{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T11:09:53Z","timestamp":1653736193560},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00115-018-0542-0","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T04:45:43Z","timestamp":1528346743000},"page":"1365-1370","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neues aus der Immuntherapie bei Multipler Sklerose"],"prefix":"10.1007","volume":"89","author":[{"given":"K.","family":"Pape","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"542_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcv.2016.12.005","volume":"88","author":"KB Alstadhaug","year":"2017","unstructured":"Alstadhaug KB, Fykse Halstensen R, Odeh F (2017) Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J\u00a0Clin Virol 88:17\u201320","journal-title":"J Clin Virol"},{"issue":"46","key":"542_CR2","first-page":"A2175","volume":"144","author":"Arzneimittelkommission der deutschen \u00c4rzteschaft","year":"2017","unstructured":"Arzneimittelkommission der deutschen \u00c4rzteschaft (2017) Therapierefrakt\u00e4re Autoimmunthrombozytopenie nach Alemtuzumab zur Behandlung einer Multiplen Sklerose. Dtsch Arztebl 144(46):A2175\u2013A2176","journal-title":"Dtsch Arztebl"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1756285616666741","volume":"10","author":"S Bittner","year":"2017","unstructured":"Bittner S, Ruck T, Wiendl H et al (2017) Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord 10:51\u201366","journal-title":"Ther Adv Neurol Disord"},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N\u00a0Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/1756285614540224","volume":"7","author":"R Bomprezzi","year":"2014","unstructured":"Bomprezzi R, Pawate S (2014) Extended interval dosing of natalizumab: a two-center, 7\u2011year experience. Ther Adv Neurol Disord 7:227\u2013231","journal-title":"Ther Adv Neurol Disord"},{"key":"542_CR6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","volume":"62","author":"DA Carson","year":"1983","unstructured":"Carson DA, Wasson DB, Taetle R et al (1983) Specific toxicity of 2\u2011chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737\u2013743","journal-title":"Blood"},{"key":"542_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1136\/jnnp-2014-310013","volume":"86","author":"T Castillo-Trivino","year":"2015","unstructured":"Castillo-Trivino T, Lopetegui I, Alarcon-Duque JA et al (2015) Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis. J\u00a0Neurol Neurosurg Psychiatr 86:931\u2013932","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"542_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","volume":"36","author":"EAA Christou","year":"2017","unstructured":"Christou EAA, Giardino G, Worth A et al (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int Rev Immunol 36:352\u2013359","journal-title":"Int Rev Immunol"},{"key":"542_CR9","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1182\/blood-2011-08-371138","volume":"118","author":"A Cuker","year":"2011","unstructured":"Cuker A, Coles AJ, Sullivan H et al (2011) A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood 118:6299\u20136305","journal-title":"Blood"},{"key":"542_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","volume":"3","author":"JP Dimarco","year":"2014","unstructured":"Dimarco JP, O\u2019connor P, Cohen JA et al (2014) First-dose effects of fingolimod: pooled safety data from three phase 3 studies. Mult Scler Relat Disord 3:629\u2013638","journal-title":"Mult Scler Relat Disord"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N\u00a0Engl J Med 362:416\u2013426","journal-title":"N Engl J Med"},{"key":"542_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1474-4422(14)70039-0","volume":"13","author":"G Giovannoni","year":"2014","unstructured":"Giovannoni G, Gold R, Selmaj K et al (2014) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol 13:472\u2013481","journal-title":"Lancet Neurol"},{"key":"542_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.msard.2016.05.010","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Kappos L, Gold R et al (2016) Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord 9:36\u201346","journal-title":"Mult Scler Relat Disord"},{"key":"542_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S et al (2017) Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. https:\/\/doi.org\/10.1177\/1352458517727603","journal-title":"Mult. Scler."},{"issue":"1","key":"542_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25119","volume":"83","author":"AL Greenfield","year":"2018","unstructured":"Greenfield AL, Hauser SL (2018) B cell therapy for multiple sclerosis: entering an era. Ann Neurol 83(1):13\u201326. https:\/\/doi.org\/10.1002\/ana.25119","journal-title":"Ann Neurol"},{"key":"542_CR16","series-title":"ECTRIMS 2017, Poster P686","volume-title":"Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies","author":"SL Hauser","year":"2017","unstructured":"Hauser SL (2017) Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies. ECTRIMS 2017, Poster P686"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N\u00a0Engl J Med 376:221\u2013234","journal-title":"N Engl J Med"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N et al (2017) Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 16:925\u2013933","journal-title":"Lancet Neurol"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/j.1476-5381.2010.00767.x","volume":"160","author":"U Hofmann","year":"2010","unstructured":"Hofmann U, Hu K, Walter F et al (2010) Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol 160:1243\u20131251","journal-title":"Br J Pharmacol"},{"key":"542_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12883-017-0848-8","volume":"17","author":"T Holmoy","year":"2017","unstructured":"Holmoy T, Von Der Lippe H, Leegaard TM (2017) Listeria monocytogenes infection associated with alemtuzumab \u2013 a case for better preventive strategies. BMC Neurol 17:65","journal-title":"BMC Neurol"},{"key":"542_CR21","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJMoa1501481","volume":"373","author":"L Kappos","year":"2015","unstructured":"Kappos L, Wiendl H, Selmaj K et al (2015) Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N\u00a0Engl J Med 373:1418\u20131428","journal-title":"N Engl J Med"},{"key":"542_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1352458516675039","volume":"23","author":"A Kavaliunas","year":"2017","unstructured":"Kavaliunas A, Manouchehrinia A, Stawiarz L et\u00a0al (2017) Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 23:1233\u20131240","journal-title":"Mult Scler"},{"key":"542_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/tera.10039","volume":"66","author":"C Lau","year":"2002","unstructured":"Lau C, Narotsky MG, Lui D et al (2002) Exposure-disease continuum for 2\u2011chloro-2\u2032-deoxyadenosine (2-CdA), a prototype teratogen: induction of lumbar hernia in the rat and species comparison for the teratogenic responses. Teratology 66:6\u201318","journal-title":"Teratology"},{"key":"542_CR24","unstructured":"Meldung der Europ\u00e4ischen Arzneimittelagentur (M\u00e4rz 2018)"},{"key":"542_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.autrev.2017.04.010","volume":"16","author":"B Merkel","year":"2017","unstructured":"Merkel B, Butzkueven H, Traboulsee AL et al (2017) Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev 16:658\u2013665","journal-title":"Autoimmun Rev"},{"key":"542_CR26","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:3043\u20133051","journal-title":"Arthritis Rheum"},{"key":"542_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L et\u00a0al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N\u00a0Engl J Med 376:209\u2013220","journal-title":"N Engl J Med"},{"key":"542_CR28","first-page":"e158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR et\u00a0al (2015) No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurology 2:e158","journal-title":"Neurology"},{"key":"542_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamaneurol.2016.0146","volume":"73","author":"H Penkert","year":"2016","unstructured":"Penkert H, Delbridge C, Wantia N et al (2016) Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol 73:757\u2013759","journal-title":"JAMA Neurol"},{"key":"542_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517699876","author":"U Ranganathan","year":"2017","unstructured":"Ranganathan U, Kaunzner U, Foster S et\u00a0al (2017) Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis. Mult Scler. https:\/\/doi.org\/10.1177\/1352458517699876","journal-title":"Mult. Scler."},{"key":"542_CR31","unstructured":"Rote-Hand-Brief (Juli 2017)"},{"key":"542_CR32","unstructured":"Rote-Hand-Brief (November 2017)"},{"key":"542_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.msard.2013.11.001","volume":"3","author":"P Schurmann","year":"2014","unstructured":"Schurmann P, Basra S, Awar OG et\u00a0al (2014) Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod. Mult Scler Relat Disord 3:408\u2013412","journal-title":"Mult Scler Relat Disord"},{"key":"542_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/1352458517694431","volume":"23","author":"M Sheikh-Taha","year":"2017","unstructured":"Sheikh-Taha M, Corman LC (2017) Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis. Mult Scler 23:872\u2013874","journal-title":"Mult Scler"},{"key":"542_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12072-017-9817-y","volume":"11","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li X, Wu S et al (2017) Risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis. Hepatol Int 11:429\u2013433","journal-title":"Hepatol Int"},{"key":"542_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1352458517694089","volume":"24","author":"C Zecca","year":"2018","unstructured":"Zecca C, Merlini A, Disanto G et al (2018) Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: observational study. Mult Scler 24:167\u2013174","journal-title":"Mult Scler"},{"key":"542_CR37","series-title":"ACTRIMS 2018, Poster LB250","volume-title":"Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH\u00ae registry","author":"LFJ Zhovtis Ryerson","year":"2018","unstructured":"Zhovtis Ryerson LFJ, Chang I, Kister I, Cutter G, Metzger R, Goldberg Jd LX, Riddle E, Yu B, Ren Z, Hotermans C, Ho P\u2011R, Campbell N (2018) Natalizumab extended interval dosing is associated with a reduction in progressive multifocal leukoencephalopathy risk in the TOUCH\u00ae registry. ACTRIMS 2018, Poster LB250"},{"key":"542_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J et\u00a0al (2016) Extended interval dosing of natalizumab in multiple sclerosis. J\u00a0Neurol Neurosurg Psychiatr 87:885\u2013889","journal-title":"J Neurol Neurosurg Psychiatr"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-018-0542-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-018-0542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T01:19:15Z","timestamp":1571447955000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-018-0542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1007\/s00115-018-0542-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,7]]},"assertion":[{"value":"7 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Pape gibt an, dass kein Interessenkonflikt besteht. F.\u00a0Zipp erhielt Forschungsf\u00f6rderungen von Teva, Merck Serono, Novartis und Bayer, au\u00dferdem war sie beratend f\u00fcr Teva, Merck Serono, Novartis, Bayer Healthcare, Biogen Idec Germany, ONO, Genzyme, Sanofi-Aventis und Octapharma t\u00e4tig mit \u00dcbernahme der Reisekosten. S.\u00a0Bittner erhielt Honorare f\u00fcr Beratungst\u00e4tigkeit und Reisekosten von Novartis, Sanofi-Genzyme, Roche und Merck Serono.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}